Epidermal growth factor receptor mutations in patients with non–small cell lung cancer
BE Johnson, PA Jänne - Cancer research, 2005 - AACR
A year has passed since mutations of the tyrosine kinase domain of the epidermal growth
factor receptor (EGFR) were discovered in patients with non–small cell lung cancer …
factor receptor (EGFR) were discovered in patients with non–small cell lung cancer …
Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non–small-cell lung cancer: current knowledge and future directions
W Pao, VA Miller - Journal of Clinical Oncology, 2005 - ascopubs.org
Purpose Gefitinib and erlotinib are small molecules that selectively inhibit epidermal growth
factor receptor (EGFR) tyrosine kinase activity. When these drugs were introduced into the …
factor receptor (EGFR) tyrosine kinase activity. When these drugs were introduced into the …
Clinical course of patients with non–small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib
Purpose: In patients with non–small cell lung cancer (NSCLC), mutations in the epidermal
growth factor receptor (EGFR) tyrosine kinase domain have been associated with sensitivity …
growth factor receptor (EGFR) tyrosine kinase domain have been associated with sensitivity …
Effect of epidermal growth factor receptor tyrosine kinase domain mutations on the outcome of patients with non–small cell lung cancer treated with epidermal growth …
PA Jänne, BE Johnson - Clinical cancer research, 2006 - AACR
Somatic mutations in the epidermal growth factor receptor (EGFR) have been identified in
patients with advanced non–small cell lung cancer who achieve dramatic clinical and …
patients with advanced non–small cell lung cancer who achieve dramatic clinical and …
Epidermal growth factor receptor mutations in non–small-cell lung cancer: Implications for treatment and tumor biology
PA Jänne, JA Engelman, BE Johnson - Journal of clinical oncology, 2005 - ascopubs.org
The epidermal growth factor receptor (EGFR) has emerged as an attractive therapeutic
target for patients with non–small-cell lung cancer (NSCLC). However, despite its almost …
target for patients with non–small-cell lung cancer (NSCLC). However, despite its almost …
Biological and clinical implications of EGFR mutations in lung cancer
T Mitsudomi, T Kosaka, Y Yatabe - International journal of clinical …, 2006 - Springer
Background Patients with non-small-cell lung cancer sometimes show a dramatic clinical
response to gefitinib or erlotinib, small-molecule tyrosine kinase inhibitors (TKI) specific for …
response to gefitinib or erlotinib, small-molecule tyrosine kinase inhibitors (TKI) specific for …
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non–small cell lung cancer patients treated with gefitinib or …
DM Jackman, BY Yeap, LV Sequist, N Lindeman… - Clinical Cancer …, 2006 - AACR
Purpose: Somatic mutations in the epidermal growth factor receptor (EGFR) have been
detected in patients with non–small cell lung cancer (NSCLC) and are associated with …
detected in patients with non–small cell lung cancer (NSCLC) and are associated with …
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib
TJ Lynch, DW Bell, R Sordella… - … England Journal of …, 2004 - Mass Medical Soc
Background Most patients with non–small-cell lung cancer have no response to the tyrosine
kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR) …
kinase inhibitor gefitinib, which targets the epidermal growth factor receptor (EGFR) …
Epidermal growth factor receptor mutations and gene amplification in non–small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials
DW Bell, TJ Lynch, SM Haserlat, PL Harris… - Journal of Clinical …, 2005 - ascopubs.org
Purpose Most cases of non–small-cell lung cancer (NSCLC) with dramatic responses to
gefitinib have specific activating mutations in the epidermal growth factor receptor (EGFR) …
gefitinib have specific activating mutations in the epidermal growth factor receptor (EGFR) …
Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous …
N Sunaga, Y Tomizawa, N Yanagitani, H Iijima, K Kaira… - Lung Cancer, 2007 - Elsevier
PURPOSE: Mutations in the epidermal growth factor receptor (EGFR) gene are associated
with increased sensitivity of non-small cell lung cancer (NSCLC) to gefitinib, an EGFR …
with increased sensitivity of non-small cell lung cancer (NSCLC) to gefitinib, an EGFR …